Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Biographical Sketch
John Sweetenham, MD, FRCP, is Professor of Medicine and Director of Clinical Research at the Cleveland Clinic Taussig Cancer Institute. Dr. Sweetenham graduated BSc (Hons), MBBS from the St Bartholomew’s Hospital Medical College & University of London in 1980, and received a Doctorate in Medicine research degree from the University of Southampton in 1989.
He is a fellow of the Royal College of Physicians of the UK, has served as head of Medical Oncology at the University of Southampton, director of Hematologic Malignancies/Bone Marrow Transplant at the University of Colorado Health Sciences Center, and subsequently was professor of Medicine and Director of Clinical Research, Arizona Cancer Center. He joined Cleveland Clinic in 2005.
Dr. Sweetenham has held extensive funding for research, has published a large body of work on hematologic malignancy, lectured in many countries on the management of lymphoma and the use of stem cell transplantation and is a member of several editorial boards and national committees.
Specialty Interests
Autologous stem cell transplantation, clinical trials, hematologic malignancies, Hodgkins disease, non-Hodgkins lymphoma, cancer, lymphoma
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the
pharmaceutical or medical device industries to help develop medical
breakthroughs or provide medical expertise or education. Cleveland Clinic
strives to make scientific advances that will benefit patient care and
support outside relationships that promise public benefit. In order for
the discoveries of Cleveland Clinic physicians' and scientists'
laboratories and investigations to benefit the public, these discoveries
must be commercialized in partnership with industry. As experts in their
fields, Cleveland Clinic physicians and scientists are often sought after
by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters,
Cleveland Clinic maintains a program that reviews these collaborations
and, when appropriate, puts measures in place to minimize bias that may
result from ties to industry. The Cleveland Clinic publicly discloses
the names of companies when (i) its physicians/scientists receive $5,000
or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its
physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its
physicians/scientists hold any equity interest for the
physician's/scientist's role as inventor, discoverer, developer, founder
or consultant.* In publicly disclosing this information, the Cleveland
Clinic tries to provide information as accurately as possible about its
physicians' and scientists' connections with industry.
As of 3/15/2010, Dr. Sweetenham has reported no financial relationship
with industry that is applicable to this listing. In general, patients
should feel free to contact their doctor about any of the relationships
and how the relationships are overseen by the Cleveland Clinic. To learn
more about the Cleveland Clinic's policies on collaborations with industry
and innovation management, go to our
Integrity in Innovation
page.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.
